Massey investigator selected for the Lymphoma Research Foundation’s Clinical Research Mentoring Program
The Lymphoma Research Foundation (LRF) has accepted VCU Massey Cancer Center researcher Victor Yazbeck, M.D., into its Clinical Research Mentoring Program (CRMP). The CRMP is a two-year program that selects up-and-coming lymphoma researchers to participate in educational courses, laboratory work and clinical studies in order to further their own research goals.
Massey scientists contribute to research involving the latest FDA-approved cancer therapies
VCU Massey Cancer Center doctors and scientists are making important discoveries involving cancer-fighting drugs recently approved by the U.S. Food and Drug Administration (FDA). Between August 2013 and July 2014, the FDA approved six new anticancer therapeutics, five of which target the unique molecular and genetic characteristics of an individual’s cancer.
As President Obama proposes national investment in precision medicine research, Massey leads the way in Virginia
President Obama recently proposed a major Precision Medicine Initiative that allocates $215 million in the federal 2016 budget for precision medicine research. Designated by the National Cancer Institute (NCI) to lead and shape the nation’s fight against cancer, Virginia Commonwealth University Massey Cancer Center has already taken steps to bring the benefits of precision medicine to Virginia. Of the President’s $215 million proposed investment, $70 million will be provided to the NCI to scale up efforts to identify the genomic drivers in cancer and to translate this information into more effective strategies to prevent and treat cancer.
Massey researcher appointed to the U.S. Preventive Services Task Force
VCU Massey Cancer Center researcher Alex Krist, M.D., M.P.H., has been appointed to the U.S. Preventive Services Task Force, an independent, volunteer panel that reviews medical research and makes evidence-based recommendations about screenings, counseling services and other clinical preventive care.
International study co-led by Massey researcher finds ovarian suppression reduces breast cancer recurrence for some young women
Results from a large international study co-led by a VCU Massey Cancer Center physician-scientist concluded that adding ovarian suppression to adjuvant therapy (post surgery) with tamoxifen substantially reduced breast cancer recurrence in young, premenopausal women with hormone-sensitive early breast cancer who received chemotherapy because of a high risk for recurrence of their cancer.